Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
Rhea-AI Summary
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapies, will release its second quarter 2025 financial results on August 4, 2025 after U.S. market close.
The company will host an investor conference call and webcast on August 5, 2025 at 8:00 AM ET / 2:00 PM CET to discuss Q2 results and provide business updates. Investors can access the call through domestic (+1-800-343-5172) or international (+1-203-518-9856) dial-in numbers using Conference ID: CLLSQ2.
Positive
- None.
Negative
- None.
News Market Reaction – CLLS
In the trading session that priced this news, CLLS declined 1.58%, reflecting a mild negative market reaction. Argus tracked a peak move of +23.6% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 3.0x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2025 ending June 30, 2025 on Monday August 4, 2025 after the close of the US market.
The publication will be followed by an investor conference call and webcast on Tuesday August 5, 2025 at 8:00 AM ET / 2:00 PM CET. The call will include the Company’s second quarter results and an update on business activities.
Details for the call are as follows:
Dial in information:
Domestic: +1-800-343-5172
International: +1-203-518-9856
Conference ID: CLLSQ2
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1727030&tp_key=10a62ee950
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
TALEN® is a registered trademark owned by Cellectis.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
